Bausch Health Companies Inc. logo

Bausch Health Companies Inc. (BHC)

Market Closed
14 Jul, 20:00
NYSE NYSE
$
6. 34
-0.08
-1.25%
$
2.37B Market Cap
- P/E Ratio
4% Div Yield
1,405,472 Volume
- Eps
$ 6.42
Previous Close
Day Range
6.23 6.41
Year Range
3.96 9.85
Want to track BHC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 15 days
Bausch + Lomb Recalls EnVista Intraocular Lenses

Bausch + Lomb Recalls EnVista Intraocular Lenses

The Canadian eyecare company said Thursday that it has made a voluntary recall of its intraocular lenses on its enVista platform.

Marketwatch | 3 months ago
Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room

Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room

Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health's potential sale of its 88% stake. The company's performance review for 2024 was strong, but the future share price trajectory hinges on whether Bausch Health will divest its majority ownership. Investors are closely watching Bausch Health's decision, as it remains the key factor influencing Bausch + Lomb's market valuation and investor sentiment.

Seekingalpha | 4 months ago
Bausch Health Q4 Earnings Recap (Reiterating Buy Rating)

Bausch Health Q4 Earnings Recap (Reiterating Buy Rating)

Bausch Health reported strong Q4 results with a 6.2% Y/Y revenue increase and positive net income, driving a 10% stock rally. Key growth drivers include Salix, Xifaxan, and Solta, with a focus on long-term growth and debt management, peaking in 2028. Positive catalysts include FDA litigation outcomes and strategic decisions around Bausch & Lomb, enhancing shareholder value and future revenue potential.

Seekingalpha | 4 months ago
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales

Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales

BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive.

Zacks | 4 months ago
Compared to Estimates, Bausch (BHC) Q4 Earnings: A Look at Key Metrics

Compared to Estimates, Bausch (BHC) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 4 months ago
Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call Transcript

Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call Transcript

Bausch Health Companies Inc. (NYSE:BHC ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conference Call Participants Les Sulewski - Truist Securities Doug Miehm - RBC Capital Michael Freeman - Raymond James Michael Nedelcovych - TD Cowen Glen Santangelo - Jefferies Operator Greetings. Welcome to the Bausch Health Fourth Quarter 2024 Earnings Call.

Seekingalpha | 4 months ago
Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates

Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates

Bausch Health (BHC) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.15 per share a year ago.

Zacks | 4 months ago
What Analyst Projections for Key Metrics Reveal About Bausch (BHC) Q4 Earnings

What Analyst Projections for Key Metrics Reveal About Bausch (BHC) Q4 Earnings

Beyond analysts' top -and-bottom-line estimates for Bausch (BHC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

Zacks | 4 months ago
Earnings Preview: Bausch Health (BHC) Q4 Earnings Expected to Decline

Earnings Preview: Bausch Health (BHC) Q4 Earnings Expected to Decline

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 5 months ago
Contact lens maker Bausch + Lomb rules out take-private deal

Contact lens maker Bausch + Lomb rules out take-private deal

Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday.

Reuters | 5 months ago
Wall Street Analysts See a 25.5% Upside in Bausch (BHC): Can the Stock Really Move This High?

Wall Street Analysts See a 25.5% Upside in Bausch (BHC): Can the Stock Really Move This High?

The mean of analysts' price targets for Bausch (BHC) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks | 5 months ago
Bausch + Lomb CEO on the negative impact of screen time on eye health

Bausch + Lomb CEO on the negative impact of screen time on eye health

Brent Saunders, Bausch and Lomb CEO, discusses how too much screen time can have a negative impact on vision.

Youtube | 6 months ago
Loading...
Load More